{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T15:59:35Z","timestamp":1769183975584,"version":"3.49.0"},"reference-count":10,"publisher":"JLE","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1684\/ejd.2018.3371","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:13:47Z","timestamp":1696864427000},"page":"711-713","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?"],"prefix":"10.1684","volume":"28","author":[{"given":"Aikaterini","family":"Patsatsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parthena","family":"Meltzanidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Trigoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Foteini","family":"Lamprou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miltiadis","family":"Kokolios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Giannakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"3371_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000443330","volume":"232","author":"FM Mendon\u00c7a","year":"2016","unstructured":"Mendon\u00c7a FM, Mart\u00edn\u2013Gutierrez FJ, R\u00edos\u2013Mart\u00edn JJ, Camacho\u2013Martinez F. Three cases of bullous pemphigoid associated with dipeptidyl peptidase\u20134 inhibitors\u2013one due to linagliptin. Dermatology 2016; 232: 249\u201353.","journal-title":"Dermatology"},{"key":"3371_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","volume":"26","author":"K Skandalis","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug\u2013induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase\u2013IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3371_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2337\/dc11-0804","volume":"34","author":"E Pasmatzi","year":"2011","unstructured":"Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase\u20134 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011; 34: e133.","journal-title":"Diabetes Care"},{"key":"3371_CR4","first-page":"24","volume":"8","author":"A Attaway","year":"2014","unstructured":"Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors. A case report and review of literature. J Dermatol Case Rep 2014; 8: 24\u20138.","journal-title":"A case report and review of literature. J Dermatol Case Rep"},{"key":"3371_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/jcpt.12397","volume":"41","author":"M Garc\u00eda","year":"2016","unstructured":"Garc\u00eda M, Aranburu MA, Palacios\u2013Zabalza I, Lertxundi U, Aguirre C. Dipeptidyl peptidase\u2013IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database. J Clin Pharm Ther 2016; 41: 368\u201370.","journal-title":"J Clin Pharm Ther"},{"key":"3371_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamadermatol.2015.2939","volume":"152","author":"R Haber","year":"2016","unstructured":"Haber R, Fayad AM, Stephan F, Obeid G, Tomb R. Bullous pemphigoid associated with linagliptin treatment. JAMA Dermatol 2016; 152: 224\u20136.","journal-title":"JAMA Dermatol"},{"key":"3371_CR7","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","volume":"136","author":"K Izumi","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Invest Dermatol 2016; 136: 2201\u201310.","journal-title":"J Invest Dermatol"},{"key":"3371_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaad.2017.09.051","volume":"78","author":"L Fania","year":"2018","unstructured":"Fania L, Salemme A, Provini A, et al. Detection and characterization of IgG, IgE and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase\u2013IV inhibitors. J Am Acad Dermatol 2018; 78: 592\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"3371_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J B\u00e9n\u00e9","year":"2016","unstructured":"B\u00e9n\u00e9 J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case\u2013noncase study in the French Pharmacovigilance Database. Br J Dermatol 2016; 175: 296\u2013301.","journal-title":"Br J Dermatol"},{"key":"3371_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","volume":"233","author":"C Schaffer","year":"2017","unstructured":"Schaffer C, Buclin T, Jornayvaz FR, et al. Use of dipeptidylpeptidase IV inhibitors and bullous pemphigoid. Dermatology 2017; 233: 401\u20133.","journal-title":"Dermatology"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2018.3371\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2018.3371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:17:02Z","timestamp":1741191422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2018.3371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3371"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2018.3371","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"11 Januar 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}